Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

First molecular test developed to detect eosinophilic esophagitis

Researchers at Cincinnati Children's Hospital Medical Center have developed the first molecular test to diagnose eosinophilic esophagitis, a chronic upper gastrointestinal disorder. The incidence of EoE has skyrocketed since it was first characterized two decades ago.

22 Nov 2013

Vaccinating kids against rotavirus may also reduce risk of seizures

A new study suggests an additional-and somewhat surprising-potential benefit of vaccinating children against rotavirus, a common cause of diarrhea and vomiting. Besides protecting kids from intestinal illness caused by rotavirus, immunization may also reduce the risk of related seizures, according to findings published in Clinical Infectious Diseases and available online.

21 Nov 2013

Intelliject to be recognized with George DiDomizio Industry Award

The Institute for Safe Medication Practices has announced that this year's George DiDomizio Industry Award is being presented to Intelliject, Inc. for pioneering advances in drug/device combination products with the Auvi-Q epinephrine auto-injector (also known as Allerject™ in Canada). Auvi-Q is the first auto-injector with audio as well as visual cues for the emergency treatment of life-threatening allergic reactions.

16 Nov 2013

European Commission grants marketing authorization for Bayer HealthCare's Xofigo injection

Bayer HealthCare announced today that the European Commission has granted marketing authorization for Xofigo (radium Ra 223 dichloride) solution for injection for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. This decision follows a positive recommendation from the European Committee for Medicinal Products for Human Use in September of this year.

15 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

Aptiom receives FDA approval to treat seizures associated with epilepsy

The U.S. Food and Drug Administration today approved Aptiom (eslicarbazepine acetate) as an add-on medication to treat seizures associated with epilepsy.

10 Nov 2013

Life-saving bone marrow transplants may also cure peanut allergies

Not only can bone marrow transplants be life-saving for children with acute lymphocytic leukemia, they may also cure peanut allergies. According to research presented during the American College of Allergy, Asthma and Immunology's Annual Scientific Meeting, a 10-year-old boy no longer had a peanut allergy after undergoing a bone marrow transplant.

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

Study finds few beneficial effects of metformin drug for cardiovascular disease in people without diabetes

Despite high expectations for the commonly used diabetes drug metformin to improve risk factors for heart disease in people without diabetes, few beneficial effects have been found in a randomised trial of patients with established cardiovascular disease, published in The Lancet Diabetes & Endocrinology.

7 Nov 2013

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results.

5 Nov 2013

CME Medical helps healthcare professionals to gain confidence in end of life and palliative care

CME Medical, is helping healthcare professionals to gain confidence in caring for patients at the end of their lives. Managing end of life care is a challenge for all health staff, as it often involves dealing with complex and emotional communication with patients and relatives and managing patient symptoms. But now highly sophisticated mannequins – which can talk and simulate signs and symptoms of advanced illness – are being used in a pioneering and unique training programme in Birmingham.

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

Houston Methodist physicians provide tips for training, protecting the entire body

For avid runners, training for the next marathon never stops. While it's important to focus on running faster or farther, Houston Methodist physicians encourage runners to expand their training regimen and are providing the following tips for training and protecting the entire body.

29 Oct 2013

Rethinking the 1930s attack on malaria may help solve modern day malaria outbreaks

A new University of Texas at Arlington study about the elimination of malaria in the 1930s American South may have significant implications for solving modern day malaria outbreaks in parts of Africa, Central and Latin America, and Asia.

24 Oct 2013

New flu vaccine offers better protection against circulating flu viruses

Last year's flu season was considered one of the strongest and deadliest in recent decades, according to the CDC. In preparation for this year's flu season, Concentra, a subsidiary of Humana Inc., offers a flu vaccine to provide greater protection against circulating flu strains.

23 Oct 2013

Psychotherapy: New treatment choice for anorexia nervosa

A large-scale study has now shown that adult women with anorexia whose disorder is not too severe can be treated successfully on an out-patient basis. Even after conclusion of therapy, they continue to make significant weight gains.

22 Oct 2013

Endoscopic ultrasound-guided drainage improves outcomes in patients with pseudocysts

Researchers report that in patients with pseudocysts with viscous debris-laden fluid, endoscopic ultrasound-guided drainage by using a combination of a nasocystic drain and transmural stents improves clinical outcomes and lowers the stent occlusion rate compared with those who underwent drainage via stents alone.

22 Oct 2013

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

19 Oct 2013

Nintedanib drug to treat NSCLC is submitted for approval from European Medicines Agency

Boehringer Ingelheim announced the submission of a Marketing Authorisation Application to the European Medicines Agency for the approval of its oral triple angiokinase inhibitor nintedanib, in combination with docetaxel, for the treatment of patients with locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy.

17 Oct 2013